Company Description
Firefly Neuroscience, Inc., an artificial intelligence company, develops, markets, and distributes medical devices and technologies that allow high-resolution visualization and evaluation of the complex neurophysiological interconnections of the human brain in North America.
The company offers the Evoke System, a system used to perform electroencephalographic (EEG) and event-related potential (ERP) assessments, which are analyzed by its cloud-based platform and returned as structured reports designed to support clinical decision-making for various diseases, including depression, anxiety, ADHD, PTSD, MCI, dementia, Parkinson's disease, bipolar disorder, schizophrenia, schizoaffective disorder, ASD, and traumatic brain injury.
It serves clinicians. Firefly Neuroscience, Inc. was founded in 2006 and is based in Kenmore, New York.
| Country | United States |
| Founded | 2006 |
| Industry | Software - Application |
| Sector | Technology |
| Employees | 17 |
| CEO | Greg Lipschitz |
Contact Details
Address: 1100 Military Road Kenmore, New York 14217 United States | |
| Phone | 888 237 6412 |
| Website | fireflyneuro.com |
Stock Details
| Ticker Symbol | AIFF |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000803578 |
| CUSIP Number | 317970101 |
| ISIN Number | US3179701012 |
| Employer ID | 54-1167364 |
| SIC Code | 7372 |
Key Executives
| Name | Position |
|---|---|
| Greg Lipschitz | Chief Executive Officer and Director |
| David DeCaprio | President, Chief Operating Officer and Director |
| Paul Krzywicki CPA, CGA | Chief Financial Officer and Company Secretary |
| Gil Issachar | Head of AI and Neuroscience |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 9, 2026 | DEF 14A | Other definitive proxy statements |
| Jul 2, 2026 | 424B3 | Prospectus |
| Jun 30, 2026 | EFFECT | Notice of Effectiveness |
| Jun 29, 2026 | PRE 14A | Other preliminary proxy statements |
| Jun 26, 2026 | 8-K | Current Report |
| Jun 23, 2026 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Jun 22, 2026 | 8-K | Current Report |
| May 20, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 20, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| May 13, 2026 | 10-Q | Quarterly Report |